NCT00308243View on ClinicalTrials.gov

Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.

PHASE1CompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions

Cystic Fibrosis

Interventions

DRUG

Sodium Pyruvate in 0.9% Sodium Chloride Solution

Trial Locations (1)

55455

University of Minnesota Medical School, The Minnesota Cystic Fibrosis Center, Minneapolis

Sponsors

Collaborators (1)

Cellular Sciences, inc.

All Listed Sponsors

collaborator

Cellular Sciences, inc.

INDUSTRY

lead

Emphycorp

INDUSTRY

NCT00308243 - Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis. | Biotech Hunter | Biotech Hunter